NASDAQ:XENE - Xenon Pharmaceuticals Stock Price, Forecast & News

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Xenon Pharmaceuticals Inc (NASDAQ:XENE) released its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.49) by $0.16. The biopharmaceutical company had revenue of $3.50 million for the quarter. View Xenon Pharmaceuticals' Earnings History.

Xenon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Xenon Pharmaceuticals.

3 Wall Street analysts have issued 1 year price targets for Xenon Pharmaceuticals' stock. Their forecasts range from $18.00 to $25.00. On average, they anticipate Xenon Pharmaceuticals' share price to reach $21.50 in the next twelve months. This suggests a possible upside of 40.6% from the stock's current price. View Analyst Price Targets for Xenon Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xenon Pharmaceuticals.

News headlines about XENE stock have been trending somewhat positive this week, according to InfoTrie. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Xenon Pharmaceuticals earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an effect on the stock's share price in the near future. View News Stories for Xenon Pharmaceuticals.

Xenon Pharmaceuticals saw a decline in short interest in the month of January. As of January 15th, there was short interest totalling 429,800 shares, a decline of 24.4% from the December 31st total of 568,400 shares. Based on an average trading volume of 177,000 shares, the short-interest ratio is currently 2.4 days. Approximately 2.1% of the shares of the stock are sold short. View Xenon Pharmaceuticals' Current Options Chain.

Some companies that are related to Xenon Pharmaceuticals include Ligand Pharmaceuticals (LGND), Constellation Pharmaceuticals (CNST), Corcept Therapeutics (CORT), Theravance Biopharma (TBPH), Esperion Therapeutics (ESPR), Innoviva (INVA), Amneal Pharmaceuticals (AMRX), BELLUS Health (BLUSF), Y-mAbs Therapeutics (YMAB), TG Therapeutics (TGTX), Endo International (ENDP), Dicerna Pharmaceuticals (DRNA), Intra-Cellular Therapies (ITCI), Nabriva Therapeutics (NBRV) and Supernus Pharmaceuticals (SUPN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Fate Therapeutics (FATE), Nektar Therapeutics (NKTR), Novavax (NVAX), Progenics Pharmaceuticals (PGNX), Exelixis (EXEL), Galmed Pharmaceuticals (GLMD), Karyopharm Therapeutics (KPTI) and Sucampo Pharmaceuticals (SCMP).

Xenon Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (3.83%) and California Public Employees Retirement System (0.23%). Company insiders that own Xenon Pharmaceuticals stock include Frank A Holler, Mohammad Azab and Simon N Pimstone. View Institutional Ownership Trends for Xenon Pharmaceuticals.

XENE stock was sold by a variety of institutional investors in the last quarter, including California Public Employees Retirement System. Company insiders that have sold Xenon Pharmaceuticals company stock in the last year include Frank A Holler, Mohammad Azab and Simon N Pimstone. View Insider Buying and Selling for Xenon Pharmaceuticals.

XENE stock was purchased by a variety of institutional investors in the last quarter, including NEA Management Company LLC. View Insider Buying and Selling for Xenon Pharmaceuticals.

Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of XENE stock can currently be purchased for approximately $15.29.

Xenon Pharmaceuticals has a market capitalization of $395.54 million and generates $310,000.00 in revenue each year. The biopharmaceutical company earns $-34,500,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Xenon Pharmaceuticals employs 89 workers across the globe.View Additional Information About Xenon Pharmaceuticals.

The official website for Xenon Pharmaceuticals is http://www.xenon-pharma.com/.

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]